Literature DB >> 22740507

Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis.

Brigitte van Zundert1, Pamela Izaurieta, Elsa Fritz, Francisco J Alvarez.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating paralytic disorder caused by dysfunction and degeneration of motor neurons starting in adulthood. Most of our knowledge about the pathophysiological mechanisms of ALS comes from transgenic mice models that emulate a subgroup of familial ALS cases (FALS), with mutations in the gene encoding superoxide dismutase (SOD1). In the more than 15 years since these mice were generated, a large number of abnormal cellular mechanisms underlying motor neuron degeneration have been identified, but to date this effort has led to few improvements in therapy, and no cure. Here, we consider that this surfeit of mechanisms is best interpreted by current insights that suggest a very early initiation of pathology in motor neurons, followed by a diversity of secondary cascades and compensatory mechanisms that mask symptoms for decades, until trauma and/or aging overloads their protective function. This view thus posits that adult-onset ALS is the consequence of processes initiated during early development. In fact, motor neurons in neonatal mutant SOD mice display important alterations in their intrinsic electrical properties, synaptic inputs and morphology that are accompanied by subtle behavioral abnormalities. We consider evidence that human mutant SOD1 protein in neonatal hSOD1(G93A) mice instigates motor neuron degeneration by increasing persistent sodium currents and excitability, in turn altering synaptic circuits that control excessive motor neuron firing and leads to excitotoxicity. We also discuss how therapies that are aimed at suppressing abnormal neuronal activity might effectively mitigate or prevent the onset of irreversible neuronal damage in adulthood. J. Cell. Biochem. 113: 3301-3312, 2012. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740507      PMCID: PMC3886915          DOI: 10.1002/jcb.24234

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  69 in total

1.  Hyperexcitability and amyotrophic lateral sclerosis.

Authors:  Matthew C Kiernan; Susanne Petri
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

2.  Differential expression of GABAA and glycine receptors in ALS-resistant vs. ALS-vulnerable motoneurons: possible implications for selective vulnerability of motoneurons.

Authors:  Louis-Etienne Lorenzo; Annick Barbe; Paule Portalier; Jean-Marc Fritschy; Hélène Bras
Journal:  Eur J Neurosci       Date:  2006-06       Impact factor: 3.386

3.  Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS.

Authors:  J E Schuster; R Fu; T Siddique; C J Heckman
Journal:  J Neurophysiol       Date:  2011-10-19       Impact factor: 2.714

4.  The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice.

Authors:  Du-Chu Wu; Diane Bérangère Ré; Makiko Nagai; Harry Ischiropoulos; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-28       Impact factor: 11.205

5.  Postnatal dendritic development in lumbar motoneurons in mutant superoxide dismutase 1 mouse model of amyotrophic lateral sclerosis.

Authors:  A A Filipchuk; J Durand
Journal:  Neuroscience       Date:  2012-02-11       Impact factor: 3.590

Review 6.  A network dysfunction perspective on neurodegenerative diseases.

Authors:  Jorge J Palop; Jeannie Chin; Lennart Mucke
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

Review 7.  Molecular biology of amyotrophic lateral sclerosis: insights from genetics.

Authors:  Piera Pasinelli; Robert H Brown
Journal:  Nat Rev Neurosci       Date:  2006-09       Impact factor: 34.870

8.  An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.

Authors:  Stefania Guareschi; Emanuela Cova; Cristina Cereda; Mauro Ceroni; Elena Donetti; Daryl A Bosco; Davide Trotti; Piera Pasinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-13       Impact factor: 11.205

9.  Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death.

Authors:  Lee J Martin; Zhiping Liu; Kevin Chen; Ann C Price; Yan Pan; Jason A Swaby; W Christopher Golden
Journal:  J Comp Neurol       Date:  2007-01-01       Impact factor: 3.215

10.  Superoxide dismutase 1 encoding mutations linked to ALS adopts a spectrum of misfolded states.

Authors:  Mercedes Prudencio; David R Borchelt
Journal:  Mol Neurodegener       Date:  2011-11-17       Impact factor: 14.195

View more
  38 in total

1.  Functional up-regulation of the M-current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons.

Authors:  Filippo Ghezzi; Laura Monni; Andrea Nistri
Journal:  J Physiol       Date:  2018-05-30       Impact factor: 5.182

2.  A Docosahexaenoic Acid-Derived Pro-resolving Agent, Maresin 1, Protects Motor Neuron Cells Death.

Authors:  Kazuki Ohuchi; Yoko Ono; Mina Joho; Kazuhiro Tsuruma; Shiho Ogami; Shinsaku Yamane; Michinori Funato; Hideo Kaneko; Shinsuke Nakamura; Hideaki Hara; Masamitsu Shimazawa
Journal:  Neurochem Res       Date:  2018-05-24       Impact factor: 3.996

Review 3.  Emerging mechanisms of molecular pathology in ALS.

Authors:  Owen M Peters; Mehdi Ghasemi; Robert H Brown
Journal:  J Clin Invest       Date:  2015-05-01       Impact factor: 14.808

4.  Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis.

Authors:  Hibiki Kawamata; Seng Kah Ng; Natalia Diaz; Suzanne Burstein; Lydie Morel; Alexandra Osgood; Brittany Sider; Haruki Higashimori; Philip G Haydon; Giovanni Manfredi; Yongjie Yang
Journal:  J Neurosci       Date:  2014-02-05       Impact factor: 6.167

5.  Circuit-Specific Early Impairment of Proprioceptive Sensory Neurons in the SOD1G93A Mouse Model for ALS.

Authors:  Soju Seki; Toru Yamamoto; Kiara Quinn; Igor Spigelman; Antonios Pantazis; Riccardo Olcese; Martina Wiedau-Pazos; Scott H Chandler; Sharmila Venugopal
Journal:  J Neurosci       Date:  2019-09-17       Impact factor: 6.167

6.  Homeostatic dysregulation in membrane properties of masticatory motoneurons compared with oculomotor neurons in a mouse model for amyotrophic lateral sclerosis.

Authors:  Sharmila Venugopal; Chie-Fang Hsiao; Takuma Sonoda; Martina Wiedau-Pazos; Scott H Chandler
Journal:  J Neurosci       Date:  2015-01-14       Impact factor: 6.167

7.  Mutant SOD1 protein increases Nav1.3 channel excitability.

Authors:  Elif Kubat Öktem; Karen Mruk; Joshua Chang; Ata Akin; William R Kobertz; Robert H Brown
Journal:  J Biol Phys       Date:  2016-04-12       Impact factor: 1.365

8.  Neurotoxicity of the Cyanotoxin BMAA Through Axonal Degeneration and Intercellular Spreading.

Authors:  Vanessa X Tan; Benjamin Lassus; Chai K Lim; Philippe Tixador; Josquin Courte; Alban Bessede; Gilles J Guillemin; Jean-Michel Peyrin
Journal:  Neurotox Res       Date:  2017-08-25       Impact factor: 3.911

9.  Changes in the Excitability of Neocortical Neurons in a Mouse Model of Amyotrophic Lateral Sclerosis Are Not Specific to Corticospinal Neurons and Are Modulated by Advancing Disease.

Authors:  Juhyun Kim; Ethan G Hughes; Ashwin S Shetty; Paola Arlotta; Loyal A Goff; Dwight E Bergles; Solange P Brown
Journal:  J Neurosci       Date:  2017-08-17       Impact factor: 6.167

10.  Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability.

Authors:  Elsa Fritz; Pamela Izaurieta; Alexandra Weiss; Franco R Mir; Patricio Rojas; David Gonzalez; Fabiola Rojas; Robert H Brown; Rodolfo Madrid; Brigitte van Zundert
Journal:  J Neurophysiol       Date:  2013-03-13       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.